Selected article for: "high dose and increase dose"

Author: Lévesque, Valérie; Millaire, Émilie; Corsilli, Daniel; Rioux-Massé, Benjamin; Carrier, François-Martin
Title: Severe immune thrombocytopenic purpura in critical COVID-19
  • Cord-id: m7m6n378
  • Document date: 2020_7_1
  • ID: m7m6n378
    Snippet: COVID-19 is a new disease with many undescribed clinical manifestations. We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient. A patient presented a severe episode of immune thrombocytopenia (< 10 × 10(9)/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and
    Document: COVID-19 is a new disease with many undescribed clinical manifestations. We report herein a case of severe immune thrombocytopenic purpura (ITP) in a critical COVID-19 patient. A patient presented a severe episode of immune thrombocytopenia (< 10 × 10(9)/L) 20 days after admission for a critical COVID-19. This thrombocytopenia was associated with a life-threatening bleeding. Response to first-line therapies was delayed as it took up to 13 days after initiation of intravenous immunoglobulin and high-dose dexamethasone to observe an increase in platelet count. COVID-19 may be associated with late presenting severe ITP. Such ITP may also be relatively resistant to first-line agents. Hematological manifestations of COVID-19, such as the ones associated with life-threatening bleeding, must be recognized.

    Search related documents:
    Co phrase search for related documents
    • absolute proof and acute respiratory syndrome: 1
    • acute ards respiratory distress syndrome and additional therapy: 1, 2
    • acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lymphadenopathy splenomegaly: 1
    • acute kidney injury and additional therapy: 1
    • acute kidney injury and liver enzyme: 1, 2, 3
    • acute kidney injury and long hospital stay: 1
    • acute kidney injury and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7
    • acute kidney injury and lymphadenopathy splenomegaly: 1
    • acute respiratory syndrome and additional therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and long hospital stay: 1, 2, 3
    • acute respiratory syndrome and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and lymphadenopathy splenomegaly: 1, 2
    • acute respiratory syndrome and lymphoproliferative disorder: 1